+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ips Cell"

From
From
From
From
Global Stem Cells Market Analysis & Forecast to 2024-2034 - Product Thumbnail Image

Global Stem Cells Market Analysis & Forecast to 2024-2034

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
From
Stem Cell Therapy Contract Manufacturing Market, 2019-2030 - Product Thumbnail Image

Stem Cell Therapy Contract Manufacturing Market, 2019-2030

  • Report
  • August 2019
  • 320 Pages
  • Global
From
From
From
From
Global Market for Stem Cells - Product Thumbnail Image

Global Market for Stem Cells

  • Report
  • March 2023
  • 139 Pages
  • Global
From
Cell Therapy Biomanufacturing: Global Markets - Product Thumbnail Image

Cell Therapy Biomanufacturing: Global Markets

  • Report
  • February 2021
  • 112 Pages
  • Global
From
Global Induced Pluripotent Stem Cells Market: 2021-2026 - Product Thumbnail Image

Global Induced Pluripotent Stem Cells Market: 2021-2026

  • Report
  • June 2021
  • 142 Pages
  • Global
From
Loading Indicator

The iPS Cell market is a rapidly growing sector within the pharmaceutical industry. It is based on the use of induced pluripotent stem cells (iPSCs) to develop treatments for a variety of diseases. iPSCs are derived from adult cells, such as skin or blood cells, and are reprogrammed to become pluripotent stem cells. These cells can then be used to create a variety of cell types, such as neurons, heart cells, and liver cells, which can be used to study diseases and develop treatments. The iPS Cell market is driven by the increasing demand for personalized medicine, as well as the potential for iPSCs to be used in regenerative medicine. Additionally, the use of iPSCs in drug discovery and development is becoming increasingly popular, as it allows for the testing of drugs on human cells in a laboratory setting. Some of the major players in the iPS Cell market include Cellular Dynamics International, Takara Bio, ReproCELL, and Axol Bioscience. Additionally, a number of biotechnology companies, such as Novocell and Pluristem, are also developing iPSC-based treatments. Show Less Read more